EU AI Act: New Compliance Guidelines for Medical Device Manufacturers Take Shape
As the EU AI Act's high-risk requirements approach their August 2026 enforcement date, detailed guidelines for medical device manufacturers clarify how AI Act obligations interact with existing EU MDR requirements.
With the EU AI Act's high-risk system requirements taking effect in August 2026, medical device manufacturers are navigating a complex dual regulatory landscape. New guidelines published in January 2026 clarify how AI Act obligations interact with the existing EU Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR).
The majority of healthcare AI systems fall into the Act's high-risk category, requiring conformity assessments, detailed technical documentation, risk management plans, high-quality training data documentation, transparent documentation, human oversight mechanisms, and continuous post-market monitoring. AI systems placed on the market before August 2, 2026, have until August 2027 to achieve full compliance.
A key concern for manufacturers has been the potential for duplicative regulatory burden. The guidelines provide some relief, clarifying that the AI Act complements rather than duplicates existing MDR requirements — manufacturers can integrate existing MDR activities to support AI Act compliance rather than building parallel systems.
The European Commission will develop additional guidelines throughout 2026 on the practical application of high-risk classification, transparency requirements, and obligations for providers and deployers. Industry groups continue to call for harmonization with FDA and MHRA frameworks to reduce the burden on companies deploying medical AI across multiple jurisdictions.